When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer

Roberto Contieri; Massimo Lazzeri; Rodolfo Hurle

doi:10.1016/j.euf.2023.03.025

When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer

Eur Urol Focus. 2023 Jul;9(4):564-566. doi: 10.1016/j.euf.2023.03.025. Epub 2023 Apr 12.

Authors

Roberto Contieri¹, Massimo Lazzeri², Rodolfo Hurle²

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy. Electronic address: contieri.ro@gmail.com.
² Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

PMID: 37059619
DOI: 10.1016/j.euf.2023.03.025

Abstract

Active surveillance (AS) has been proposed as a possible management option for patients with recurrent low-grade non-muscle-invasive bladder cancer. Recent studies suggest that AS is a safe and effective management strategy. Nevertheless, a consensus statement is needed to standardize inclusion criteria and follow-up schedules.

MeSH terms

Humans
Non-Muscle Invasive Bladder Neoplasms*
Risk
Urinary Bladder Neoplasms* / epidemiology
Urinary Bladder Neoplasms* / therapy
Watchful Waiting